Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Regulated financial information

Bone Therapeutics Provides Business Update for the First Quarter of 2016

  • Read more about Bone Therapeutics Provides Business Update for the First Quarter of 2016

Bone Therapeutics announces half-year results for 2016

  • Read more about Bone Therapeutics announces half-year results for 2016

Bone Therapeutics Business Update for the Third Quarter of 2016

  • Read more about Bone Therapeutics Business Update for the Third Quarter of 2016

Bone Therapeutics Reports Full Year 2016 Results

  • Read more about Bone Therapeutics Reports Full Year 2016 Results

Bone Therapeutics Business Update for the First Quarter of 2017

  • Read more about Bone Therapeutics Business Update for the First Quarter of 2017

Bone Therapeutics announces half-year results for 2017

  • Read more about Bone Therapeutics announces half-year results for 2017

Bone Therapeutics Business Update for the Third Quarter of 2017

  • Read more about Bone Therapeutics Business Update for the Third Quarter of 2017

Bone Therapeutics Reports Full Year 2017 Results

  • Read more about Bone Therapeutics Reports Full Year 2017 Results

Bone Therapeutics announces half-year results for 2018

  • Read more about Bone Therapeutics announces half-year results for 2018

Bone Therapeutics Business Update for the Third Quarter of 2018

  • Read more about Bone Therapeutics Business Update for the Third Quarter of 2018

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Regulated financial information
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions